ArticleBioMed research international2013
The prognostic significance of CD44V6, CDH11, and β-catenin expression in patients with osteosarcoma.
Article in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Prognostic Significance of β-Catenin Expression in Osteosarcoma: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Diagnostic accuracy of CD44V6 for osteosarcoma: a meta-analysis.Journal of orthopaedic surgery and research · 2016Pooled it
- Prognostic significance of CD44V6 expression in osteosarcoma: a meta-analysis.Journal of orthopaedic surgery and research · 2015Pooled it
- Prognostic role of CD44 expression in osteosarcoma: evidence from six studies.Diagnostic pathology · 2014Pooled it
- Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).International journal of oncology · 2024Review
- Cdh11: Roles in different diseases and potential value in disease diagnosis and treatment.Biochemistry and biophysics reports · 2023Review
- The clinical significance of CD44v6 in malignant and benign primary bone tumors.BMC musculoskeletal disorders · 2023Article
- Zinc oxide nanoparticles inhibit osteosarcoma metastasis by downregulating β-catenin via HIF-1α/BNIP3/LC3B-mediated mitophagy pathway.Bioactive materials · 2023Article
- A 3D-printed scaffold-based osteosarcoma model allows to investigate tumor phenotypes and pathogenesis in an in vitro bone-mimicking niche.Materials today. Bio · 2022Article
- CD44 In Sarcomas: A Comprehensive Review and Future Perspectives.Frontiers in oncology · 2022Review
- High expression of Dll4 and CD44V6 is associated with clinicopathological characteristics and poor prognosis in osteosarcoma patients.Translational cancer research · 2021Article
- Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.Journal of the National Cancer Institute · 2019Article
- A positive feedback loop consisting of C12orf59/NF-κB/CDH11 promotes gastric cancer invasion and metastasis.Journal of experimental & clinical cancer research : CR · 2019Article
- CD44 splice isoform switching determines breast cancer stem cell state.Genes & development · 2019Article
- Article
- Attaining threshold antibody cytotoxicity for selective tumor cell destruction: an opinion article.Oncotarget · 2018Review
- Article
- Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma.Cell proliferation · 2018Article
- Article
- Structural Equation Modeling and Whole-Genome Scans Uncover Chromosome Regions and Enriched Pathways for Carcass and Meat Quality in Beef.Frontiers in genetics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to examine the expression of and the relationship between CD44V6, CDH11, and β-catenin. The expression of these cell adhesion molecules was detected in 90 osteosarcoma and 20 osteochondroma specimens using immunohistochemistry. Associations between these parameters and clinicopathological data were also examined. The expression rates of CD44V6, CDH11, and β-catenin were 25.0% (5/20), 70.0% (14/20), and 20.0% (4/20) in osteochondroma specimens, respectively. Compared to osteochondromas, the proportions of expression of CD44V6 and β-catenin in osteosarcoma specimens increased to 65.6% (59/90) and 60.0% (54/90), respectively. However, the expression rate of CDH11 in osteosarcomas was reduced to 40.0% (36/90). The expression of these markers was significantly associated with metastasis and overall survival (P < 0.05). Survival analysis revealed that patients with increased expression of CD44V6 and β-catenin as well as decreased expression of CDH11 were correlated with a shorter survival time. Multivariate analysis indicated that clinical stage, metastasis status, and the expression of CD44V6, CDH11, and β-catenin were found to be associated with overall survival. Further, the expression of β -catenin and that of CD44V6 were positively correlated with each other. Thus, our results indicated abnormal expression of CD44V6, CDH11, and β-catenin in osteosarcomas and osteochondromas, which may provide important indicators for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.